Idibell names Jaume Reventós new director
He previously served as head of the VHIR Research Unit in Biomedicine and Translational Oncology
Jaume Reventós has been named director of the Bellvitge Biomedical Research Institute (Idibell). Co-founder of Transbiomed and previously head of the Research Unit in Biomedicine and Translational Oncology at the Vall d’Hebron Research Institute (VHIR), Reventós’ nomination as director of the institute has been approved by the Idibell Board of Trustees. He is taking over for Emilià Pola, who led the center for five years until last September and is now executive director of ICREA.
Reventós founded the VHIR spin-off Transbiomed in 2007 alongside Andreas Doll, Miguel Abal and Raimon Forés. In 2013, the company developed a test for early diagnosis of prostate cancer and began research into biomarkers for ovarian cancer.
The Board of Trustees that approved Reventós’ nomination consists of the Catalan Institute of Oncology (ICO), the University of Barcelona (UB), the L’Hospitalet de Llobregat City Council, the Catalan ministries of Health and Economy and Knowledge and the University Hospital of Bellvitge and Hospital of Viladecans, which belong to the Catalan Institute of Health (ICS).
More information is available in the Idibell article.